Mr & Mrs Ko Chi-Ming Centre for Parkinson's Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Mr & Mrs Ko Chi-Ming Centre for Parkinson's Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.
Drug Discov Today. 2019 Feb;24(2):595-605. doi: 10.1016/j.drudis.2018.11.001. Epub 2018 Nov 8.
Neurodegenerative diseases (NDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), threaten the health of an ever-growing number of older people worldwide; so far, there are no effective cures. Significant efforts have been devoted to developing new drugs for NDs in recent years, and some small molecules have been shown to be promising in preclinical studies. However, the major challenge for brain-targeting drugs is how to efficiently deliver the drugs across the blood-brain barrier (BBB) to desired targets. To address this issue, liposomal delivery systems have proved to be ideal carriers for neuroprotective small molecules. Here, we summarize recent advances in the brain-targeting liposomal delivery of small hydrophobic molecules (SHMs) and propose strategies for developing liposomal SHMs as disease-modifying neurotherapeutics for NDs.
神经退行性疾病（NDs），包括阿尔茨海默病（AD）和帕金森病（PD），威胁着全球越来越多老年人的健康；到目前为止，还没有有效的治疗方法。近年来，人们为开发治疗 NDs 的新药做出了巨大努力，一些小分子在临床前研究中表现出了很大的希望。然而，针对脑部的药物的主要挑战是如何有效地将药物穿过血脑屏障（BBB）递送到靶标。为了解决这个问题，脂质体递药系统已被证明是神经保护小分子的理想载体。在这里，我们总结了近年来针对小分子的脑靶向脂质体传递的最新进展，并提出了将脂质体小分子作为治疗 NDs 的疾病修饰神经治疗药物的发展策略。
